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Abstract
Background: Strongyloidiasis is a truly neglected tropical disease, but its public health significance is far from being
negligible. At present, only a few drugs are available for the treatment and control of strongyloidiasis.
Methodology/Principal Findings: We investigated the activity of tribendimidine against third-stage larvae (L3)o f
Strongyloides ratti in vitro and against juvenile and adult stages of the parasite in vivo. S. ratti larvae incubated in PBS buffer
containing 10–100 mg/ml tribendimidine died within 24 hours. A single 50 mg/kg oral dose of tribendimidine administered
to rats infected with 1-day-old S. ratti showed no effect. The same dose administered to rats harboring a 2-day-old infection
showed a moderate reduction of the intestinal parasite load. Three days post-exposure a significant reduction of the
immature worm burden was found. Administration of tribendimidine at doses of 50 mg/kg and above to rats harboring
mature S. ratti resulted in a complete elimination of the larval and adult worm burden. For comparison, we also
administered ivermectin at a single 0.5 mg/kg oral dose to rats infected with adult S. ratti and found a 90% reduction of
larvae and a 100% reduction of adult worms.
Conclusion/Significance: Tribendimidine exhibits activity against S. ratti in vitro and in vivo. The effect of tribendimidine in
humans infected with S. stercoralis should be assessed.
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Introduction
An estimated 30–100 million people are infected with Strongyloides
stercoralis, the causative agent of strongyloidiasis, and yet this is a truly
neglected tropical disease [1]. One explanation is that current
diagnostictools havelimitations [2].WhilstS. stercoralismainlyoccurs
in tropical and subtropical areas, endemic foci also occur in
temperate regions such as Spain or the United States [3]. Serious
clinical problems have been observed in S. stercoralis-infected patients
who are immunocompromised due to a co-infection with human T-
cell leukaemia virus type 1 (HTLV-1) or HIV, or corticosteroid-
treated patients [4]. However,the global burden ofstrongyloidiasis is
currently not known. The growing evidence that an infection with S.
stercoralis is a risk factor for biliary tract cancer needs to be considered
when estimating the burden of strongyloidiasis [5].
As with other nematodes (Ascaris lumbricoides, hookworms and
Trichuris trichiura) and trematodes (e.g. Schistosoma spp.), there are only
a few drugsavailable forthe treatmentand control of strongyloidiasis
[6]. Albendazole and mebendazole were found to be safe, but
multiple treatment courses repeated over several weeks were
required to achieve acceptable cure rates [7]. Another benzimid-
azole, thiabendazole, is highly efficacious (two treatment courses of
25–50 mg/kg are commonly given for 3–4 days 2 weeks apart), but
severe adverse events, including liver dysfunction and neuropsychi-
atric symptoms, have been observed [8]. Ivermectin, a semi-
synthetic macrocyclic lactone, which was developed as a veterinary
anthelmintic,issafeandefficacious,andisnowthe drug ofchoicefor
strongyloidiasis [9]. Ivermectin resistance in humans infected with S.
stercoralishasnotbeenreportedthusfar,buthostandparasite-specific
resistance to the drug has been reported in veterinary medicine [9].
Tribendimidine is an aminophenyldimidine derivative of ami-
dantel. Tribendimidine is safe and has a broad spectrum of activity
against numerous nematode species, including A. lumbricoides,
Enterobius vermicularis and the hookworms (Ancylostoma duodenale and
Necator americanus) [10]. Tribendimidine has been approved by
Chinese regulatory authorities in 2004 [10] and phase IV trials have
been completed recently [11]. Efforts are ongoing to secure a
western registration for tribendimidine, in order for the treatment to
be considered for global soil-transmitted helmithiasis control usage.
In our recent work, we have documented the in vivo activity of
tribendimidine against a number of trematodes, namely the
intestinal fluke Echinostoma caproni [12] and the two liver flukes
Clonorchis sinensis and Opisthorchis viverrini [13].
Here, we investigated the in vitro activity of tribendimidine
against third-stage larvae (L3)o fStrongyloides ratti. Moreover, we
evaluated the dose-response relationships of single oral doses of
tribendimidine against adult S. ratti harbored in rats, and assessed
the in vivo activity of tribendimidine against different immature
stages of the parasite in the rat model.
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Animals and parasites
All in vivo studies presented here were carried out at the Swiss
Tropical Institute (Basel, Switzerland) in accordance with Swiss
national animal welfare regulations (permission no. 2081).
Male Wistar rats (n=48, age: 3 weeks, weight: ,80 g) were
purchased from RCC (Itingen, Switzerland). Rats were kept in
groups of 4 in macrolon cages under environmentally-controlled
conditions (temperature: ,25uC; humidity: ,70%; 12 h light and
12 h dark cycle) and acclimatized for 1 week.
The S. ratti life cycle has been maintained at our institute for 15
years by serial passage through rats. S. ratti L3 were obtained from
the faeces of infected rats following standardized procedures based
on the Baermann technique [14].
Drugs
Tribendimidine was synthesized and kindly provided by the
Department of Pharmaceutics, National Institute of Parasitic
Diseases, Chinese Center for Disease Control and Prevention
(Shanghai, China). Ivermectin was purchased from Sigma Aldrich
(Buchs, Switzerland). A stock solution of tribendimidine at 10 mg/
ml was prepared with 60% DMSO for the in vitro studies. For the in
vivo studies, both drugs were prepared in homogenous suspensions
in 7% Tween-80 and 3% ethanol before oral administration.
In vitro studies
Freshly harvested S. ratti L3 were washed 3 times with PBS
buffer and incubated in 6-well microtiter plates (Costar) containing
4 ml PBS buffer (pH 7.3). 800 S. ratti L3 were used for each control
and experimental group. The worms were incubated in three
serial drug dilutions of tribendimidine, i.e. 100, 10 and 1 mg/ml
for up to 96 hours (h). Each experiment was carried out in
triplicate and then repeated once. The control wells contained
0.06% DMSO. Cultures were kept at 25uC in an atmosphere of
5% CO2. Larval counts were performed immediately after
exposure and at 1, 2, 24, 48, 72 and 96 h post-exposure under a
dissecting microscope.
In vivo studies
Rats were infected subcutaneously with 1300 freshly harvested
S. ratti L3. To analyse the effect of tribendimidine on adult S. ratti,5
days post-exposure, 5 groups with 4 rats each were administered
tribendimidine at doses of 200, 100, 50, 25 and 12.5 mg/kg,
respectively (first set of experiments: doses 50–200 mg/kg; second
set of experiments: doses 12.5 and 25 mg/kg). Ivermectin was
given to 4 rats at a single 0.5 mg/kg oral dose. Eight rats were left
untreated and served as controls.
Stool samples from all rats investigated were collected shortly
before treatment and daily for 4 days after treatment. From each
treatment group 250 mg stool was homogenized with 2.5 ml PBS
buffer and 10 aliquots of 10 ml stool suspension were analyzed for
the presence of rhabditiform larvae. The average rhabditiform
larvae count per gram of stool was calculated.
Seven days post-treatment rats were euthanised by CO2.A t
necropsy the intestine was removed from the pylorus to the
ileocecal valve, placed in a Petri dish containing 10 ml of PBS
buffer (pH 7.3) opened longitudinally and incubated for 3 h. Ten
aliquots of 10 ml PBS were analyzed for the presence of
rhabditiform larvae and adults and the average worm counts
were recorded.
To determine whether tribendimidine has an effect on the tissue
stages of S. ratti, 12 rats were treated intragastrically, either on day
1, 2 or 3 post-exposure (4 rats each), with a single 50 mg/kg oral
dose of tribendimidine. One group with 4 infected but untreated
rats served as control. Stool samples were collected between days 5
and 9 post-exposure and processed as described above. Rats were
sacrificed on day 9 post-exposure and the intestine was analysed
for the presence of S. ratti adults and rhabditiform larvae as
explained before.
Statistical analysis
Statistical analyses were done with version 2.4.5 of Statsdirect
statistical software (Statsdirect Ltd; Cheshire, UK). The effect of
tribendimidine was assessed by comparing the mean number of S.
ratti rhabditiform larvae in the stool and S. ratti adults and
rhabditiform larvae in the intestine in the treatment group with the
mean number of larvae and adults in the respective control group.
The responses between the medians of the treatment and control
groups regarding larvae and stool and larvae and adults in the
intestines were analysed with the Kruskal-Wallis (KW) test.
Differences in medians were considered to be significant at a
significance level of 0.05.
Results
In vitro findings
Table 1 summarizes the effect of S. ratti L3 after exposure to
tribendimidine at different concentrations in vitro. S. ratti exposed
to tribendimidine at 10 or 100 mg/ml contracted immediately and
had a coiled shape appearance. The worms died within 24 h. No
effect was observed with the lowest concentration (1 mg/ml) of
tribendimidine: 66.6% of S. ratti were still active after an
incubation period of 72 h. Ninety-six h post-incubation 58.4%
of S. ratti showed no movement when exposed to this concentra-
tion, similar to the control group, where 60.0% of the worms were
found to be inactive.
Effect of tribendimidine on adult S. ratti: dose-response
relationship
Figure 1 shows the effect of tribendimidine on S. ratti
rhabditiform larvae harvested from rat fecal samples as assessed
by quantitative stool examination. In the first set of experiment
(evaluating single 50, 100 and 200 mg/kg oral doses of
tribendimidine) on 5 daily stool examinations, between 3300 (6
days post-exposure) and 10,000 (9 days post-exposure) rhabditi-
form larvae per gram of stool were estimated in the group of
Author Summary
Although an estimated 30–100 million individuals are
infected with the parasitic roundworm Strongyloides
stercoralis, which can cause strongyloidiasis, it is a so-
called neglected tropical disease. There are only very few
drugs available for treating strongyloidiasis. We evaluated
the strongyloicidal properties of the anthelmintic com-
pound tribendimidine in vitro and in an animal model.
Larvae from S. ratti incubated in PBS buffer containing 10–
100 mg/ml tribendimidine died within 24 hours. Tribendi-
midine showed a significant activity against adult S. ratti
harbored in rats: oral administration of tribendimidine at
single doses of 50 mg/kg and above resulted in a
complete elimination of larvae and adult worms. A single
50 mg/kg oral dose of tribendimidine was less effective
against the migrating tissue stages, in particular the 1- and
2-day-old S. ratti. In view of our findings, the effect of
tribendimidine against S. stercoralis infections in humans
should be assessed.
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obtained from rats treated with single 100 or 200 mg/kg oral
doses of tribendimidine and 0.5 mg/kg ivermectin commencing
48 h post-treatment. While no larvae were found at 48 h and 96 h
post-treatment with 50 mg/kg tribendimidine, a low mean of 100
larvae per gram of stool was estimated 72 h post- treatment
(Figure 1). Untreated rats in the second set of experiment (assessing
the activity of 12.5 and 25 mg/kg tribendimidine) passed between
1000 and 18,600 S. ratti rhabditiform larvae per gram of stool on
days 5 to 9 post-exposure. Larvae were also present in the stools of
rats treated with 25 and 12.5 mg/kg tribendimidine; the highest
numbers of rhabditiform larvae were detected 72 h post-
treatment, namely 1300 and 2900 larvae per gram of stool in
rats treated with 25 and 12.5 mg/kg, respectively (Figure 2).
However, treatment had a significant effect on larvae presence in
stools (KW=67.1, degree of freedom (df)=2; P , 0.001).
The effect of tribendimidine against S. ratti rhabditiform larvae
and adults in the intestine, as assessed by worm burden reduction,
is summarized in Table 2. The untreated control rats harbored a
mean of 1012 S. ratti rhabditiform larvae and 413 adult worms in
their intestines. Tribendimidine given at doses of 50, 100 and
200 mg/kg resulted in complete elimination of larvae and adult
worms.
For comparison, ivermectin administered at 0.5 mg/kg
achieved a significant larval reduction (90.0%; KW=4.58, P=
0.032) and a complete elimination of adult worms.
Table 1. Observed immobility of S. ratti L3 after exposure in vitro to tribendimidine at three different concentrations.
Drug Drug concentration (mg/ml) % of worms inactive (SD) after incubation for
5m i n 1h 2h 2 4h 4 8h 7 2h 9 6h
Control No treatment 40.0 (28.5) 55.0 (7.1) 36.7 (20.1) 23.4 (23.2) 26.7 (16.5) 50.0 (28.6) 60.0 (14.1)
Tribendimidine 1 30.0 (26.7) 0 (0) 33.4 (2.4) 23.4 (6.3) 5.0 (7.1) 33.4 (9.4) 58.4 (17.0)
10 30.0 (28.6) 48.3 (6.2) 70.0 (32.4) 100 (0) - - -
1 0 0 3 6 . 6 ( 3 5 . 6 ) 9 8 . 4 ( 2 . 4 ) 1 0 0 ( 0 ) ----
SD: standard deviation.
doi:10.1371/journal.pntd.0000136.t001
Figure 1. Mean (SE) fecal larvae output of 4 S. ratti-infected rats that remained untreated and 4 S. ratti-infected rats that were
treated on day 5 post-exposure with either 0.5 mg/kg ivermectin, or either 50, 100 or 200 mg/kg tribendimidine.
doi:10.1371/journal.pntd.0000136.g001
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larvae in their intestines. Tribendimidine at 25 mg/kg produced a
91.4% reduction of S. ratti larvae and a complete reduction of adult
worms. When tribendimidine was given at 12.5 mg/kg, the adult
worm burden was reduced by 83.3% and the larval burden by
54.4%. There was a significant difference in the larval (KW=6.83,
df=2, P=0.041) and the adult worm (KW=9.46, df=2, P=0.009)
burden between these 2 treatments and the control groups.
Effect of tribendimidine on juvenile S. ratti
Figure 3 shows the effect of tribendimidine given 1–3 days post-
exposure on S. ratti rhabditiform larvae present in stool. The
number of rhabditiform larvae in the control group increased from
700 on day 5 post-exposure to 6700 rhabditiform larvae per gram
of stool 4 days later. A larval reduction ranging from 30.6% (6 days
post-exposure) to 73.1% (9 days post-exposure) was observed in
fecal samples of rats treated with 50 mg/kg tribendimidine on day
Figure 2. Mean (SE) fecal larvae output of 4 S. ratti-infected rats that remained untreated and S. ratti-infected rats treated on day 5
post-exposure with either 12.5 or 25 mg/kg tribendimidine.
doi:10.1371/journal.pntd.0000136.g002
Table 2. Effect of ivermectin and tribendimidine (different doses) against adult S. ratti harbored in rats.
Treatment
Dose
(mg/kg)
No. of rats
cured*/
investigated
Mean larval
burden (SD)
Mean adult
worm burden
(SD)
Total larval
burden
reduction (%) KW P-value
Total adult
worm burden
reduction (%) KW P-value
Control 1
a No treatment 0/4 1012 (640) 413 (284) - - - - - -
Control 2
b No treatment 0/4 2025 (1001) 750 (387) - - - - - -
Tribendimidine 12.5
b 0/4 925 (846) 125 (96) 54.3 6.83 0.041 83.3 9.46 0.008
25
b 0/4 175 (150) 0 91.4 100
50
a 4/4 0 0 100 14.61 0.002 100 10.28 0.016
100
a 4/4 0 0 100 100
200
a 4/4 0 0 100 100
Ivermectin 2.5
a 4/4 150 (150) 0 90 4.58 0.032 100 4.0 0.045
*number of rats without S. ratti.
afirst experiment.
bsecond experiment.
KW: Kruskal-Wallis.
SD: standard deviation.
doi:10.1371/journal.pntd.0000136.t002
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on day 2 post-exposure, a reduction of rhabditiform larvae ranging
between 50.0% (7 days post-exposure) and 83.6% (9 days post-
exposure) was observed. Finally, no rhabditiform larvae were found
in 5 consecutive stool samples from rats treated with 50 mg/kg of
tribendimidine on day 3 post-exposure. Administration of
tribendimidine to rats harboring tissue stages of S. ratti had a
significant effect on the presence of larvae in stool (KW=14.1;
df=3, P=0.002).
Table 3 summarizes observed larvae and adult worm burden
reductions in the intestines of rats following treatment with
tribendimidine. Administration of a single 50 mg/kg oral dose of
tribendimidine on day 1 post-exposure to S. ratti-infected rats
showed no effect on the intestinal larval and adult parasite load.
Treatment of infected rats 48 h post-exposure with a single
50 mg/kg oral dose of tribendimidine resulted in larvae and adult
worm burden reductions of 41.0–61.5%. Finally, when tribendi-
midine (50 mg/kg) was given 72 h post-exposure, a 98.9%
reduction of larvae in the intestines was observed. There was a
significant difference between the number of larvae (KW=9.65,
P=0.021) and adult worms (KW=6.29, P=0.098) recovered
from the intestines of treated and non-treated control rats.
Figure 3. Mean (SE) fecal larvae output of 4 S. ratti-infected rats that remained untreated and S. ratti-infected rats treated with
50 mg/kg tribendimidine either on day 1, 2 or 3 post-exposure.
doi:10.1371/journal.pntd.0000136.g003
Table 3. Effect of a single 50 mg/kg oral dose of tribendimidine against immature stages of S. ratti harbored in rats.
Treatment Treatment day post-exposure (stage)
No. of rats
cured*/
investigated
Mean larval
burden (SD)
Mean adult
worm burden
(SD)
Total larval
burden
reduction (%)
Total adult
worm burden
reduction (%)
Control No treatment 0/4 2375 (1190) 150 (58) - -
Tribendimidine 1 (L3 larvae in lungs or in cranial or nasal cavities)
a 0/4 2800 (2546) 225 (263) 0 0
2 (some preadolescent stages in intestine)
a 0/4 1400 (716) 50 (58) 41.1 61.5
3 (some preadolescent stages in intestine)
a 0/4 25 (50) 50 (58) 98.9 61.5
*number of rats without S. ratti.
aHarder et al. (2001) [25].
Kruskal-Wallis (KW) testing difference in total larval burden reduction (KW=9.66, df=3, P=0.021) and adult worm burden reduction (KW=6.29, df=3, P=0.098).
SD: standard deviation.
doi:10.1371/journal.pntd.0000136.t003
Activity of Tribendimidine against S. ratti
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Discovered in the mid-1980s [15], detailed laboratory investi-
gations and subsequent clinical testing for safety and efficacy have
led to tribendimidine being registered in China, in early 2004, as
an anthelmintic drug with a broad spectrum of activity. In
experimentally-infected animals, tribendimidine showed excellent
activity against major nematode infections, i.e. A. lumbricoides and
the hookworms, particularly N. americanus [10]. Tribendimidine
has also shown excellent activity against a number of trematodes,
e.g. C. sinensis, E. caproni and O. viverrini in different rodent models
[12,13]. Here, we extended in vitro and in vivo activity testing of
tribendimidine to yet another helminth, namely S. ratti, which is a
commonly used experimental model of a nematode infection [16].
A single 50 mg/kg oral dose of tribendimidine administered to rats
harboring adult S. ratti resulted in complete worm burden
reductions. The same dose given to rats infected with juvenile S.
ratti revealed a significant reduction of the larval burden already 3
days post-exposure. However, no effect was found when
tribendimidine was administered 1 day post-exposure and only a
moderate effect was observed at day 2 post-exposure. Whether
immature S. ratti are less sensitive to tribendimidine or whether
drug levels are lower in the tissues where larvae reside at this age
remains to be investigated. Further studies are necessary to
investigate the effect of higher and also multiple doses of
tribendimidine against immature S. ratti.
It is interesting to compare our results with a 2-day treatment
regimen of ivermectin, the current drug of choice for strongyloi-
diasis. Two doses of 0.3 mg/kg ivermectin resulted in complete
worm burden reduction of adult S. ratti in mice [17]. A 2-day dose
of 0.5 mg/kg ivermectin was highly efficacious against the
migrating and lung stages of this parasite, resulting in worm
burden reductions of 91–96% [18]. In our own experiment, a
single 0.5 mg/kg oral dose of ivermectin resulted in a 90% larval
reduction and a complete elimination of adult worms. On the
other hand, albendazole or thiabendazole were found to be less
efficacious against immature S. ratti even when multiple doses were
administered. For example, a 3-day treatment schedule of 50 mg/
kg albendazole and thiabendazole administered on days 4–6 post-
exposure cured rats infected with adult S. ratti. However, no or
only low cure rates (up to 33%) were observed when these drugs
were administered during the lung and tissue stages of the parasite
on days 1, 2 and 3 post-exposure [19]. Interestingly, 2 doses of
50 mg/kg mebendazole were found to be highly efficacious
against the tissue stages of S. ratti [20].
Our in vitro studies revealed that worms incubated in the
presence of 100 mg/ml tribendimidine died within 2 h. The
worms had a coiled appearance. It has been suggested that
tribendimidine, which, similar to amidantel is biotransformed into
p-(1-dimethlyamino ethylimino) aniline (S.H. Xiao, pers. comm.),
acts as agonist at the level of the acetylcholine receptor [21]. The
rapid onset of action of tribendimidine is supported by our in vivo
studies since no larvae were found in stools of rats treated with at
least 50 mg/kg of tribendimidine 48 h post-treatment. A previous
investigation showed that tribendimidine acted similarly rapidly
when it was administered to mice infected with the intestinal
trematode E. caproni. Scanning electron microscopic investigations
revealed that severe damage of the tegument already occurred 2 h
after drug administration and 8 h post-treatment the majority of
worms had been expelled [12].
Concluding, we have documented in vitro and in vivo activities
of tribendimidine against S. ratti. Our findings warrant further
investigations, which is justified as follows. First, discovery and
development of novel anthelmintic drugs in general [22,23] and
strongylocidal drugs in particular, is limited. Hence, over the past
decade only a few compounds have been examined in the S. ratti-
rat model [24,25]. Second, tribendimidine has recently been
registered in China as an anthelmintic drug, and it might thus be
deployed as an additional control tool against major helminth
infections [26]. Efforts are ongoing to pursue registration of
tribendimidine in a 1
st tiered regulatory agency so that the drug
could eventually be integrated in global helminth control
programs. Since many helminth infections show large geograph-
ical overlaps, it will be important to monitor the effect of
tribendimidine on concomitant infections of different nematodes
and trematodes. We are currently in the process of examining the
effect of tribendimidine against S. stercoralis in people co-infected
with this parasitic roundworm and other nematodes and
trematodes.
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